Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
RESEARCH TOOLSreports
Acrivon Therapeutics, Inc. (ACRV) Stock Price & Analysis
119 Followers
ACRV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.19 - $13.20
Previous Close$7.33
Volume3.55K
Average Volume (3M)142.68K
Market Cap
$225.09M
Enterprise Value$120.80M
Total Cash (Recent Filing)$109.97M
Total Debt (Recent Filing)$4.45M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 09, 2024EPS Estimate
-$0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding30,876,932
10 Day Avg. Volume145,595
30 Day Avg. Volume142,679
Standard Deviation0.27
R-Squared0.03
Alpha-0.00869
Financial Highlights & Ratios
Price to Book (P/B)1.68
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue901.48
Enterprise Value/Gross Profit901.48
Enterprise Value/Ebitda-1.81
Forecast
1Y Price Target
$23.00Price Target Upside215.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Acrivon Therapeutics, Inc. News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyMonotherapy treatment in late line Pt-resistant ovarian cancer and endometrial cancer showed high response rates.
Financial StabilityACRV placed a $130M private placement financing at a premium, which extends cash runway into 2H26.
Platform ValidationInitial ACR-368 data in conjunction with ACR-368 OncoSignature assay provided validation of Acrivon Therapeutics' platform technology in patients.
Bears Say
EfficacySpider plot shows nice stabilization following initial tumor reduction but depth of response is not robust.
EnrollmentEnrollment for the trial in bladder cancer is lagging compared to ovarian and endometrial cancers.
SafetyThree patients had dose limiting toxicities (DLTs), including Grade 3 Fridericia-corrected QT prolongation and fatigue at 350 mg, and grade 3 rash at 260 mg.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $3.19 and its highest was $13.20 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is Aug 09, 2024 which is in 18 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on May 14, 2024. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.84 by $0.11.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -$0.59.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 30,876,932 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.84. Following the earnings report the stock price went down -1.415%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Among the largest hedge funds holding Acrivon Therapeutics, Inc.’s share is RA Capital Management. It holds Acrivon Therapeutics, Inc.’s shares valued at 34M.
---
Acrivon Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.00 (215.50% Upside)
$23.00 (215.50% Upside)
Blogger Sentiment
Bullish
ACRV Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 52.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.6%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.34%
12-Months-Change
Fundamentals
Return on Equity
-47.77%
Trailing 12-Months
Asset Growth
-29.19%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
---
ACRV Stock 12 Month Forecast
Average Price Target
$23.00
▲(215.50% Upside)
Technical Analysis
Best Analysts Covering ACRV
1 Year
1 Year Success Rate
2/5 ratings generated profit
1 Year Average Return
+1.08%
reiterated a buy rating 2 months ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +1.08% per trade.
---